vs

Side-by-side financial comparison of Byrna Technologies Inc. (BYRN) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

Byrna Technologies Inc. is the larger business by last-quarter revenue ($35.2M vs $19.6M, roughly 1.8× STANDARD BIOTOOLS INC.). Byrna Technologies Inc. runs the higher net margin — 9.5% vs -177.4%, a 187.0% gap on every dollar of revenue. On growth, Byrna Technologies Inc. posted the faster year-over-year revenue change (26.0% vs -11.5%). Byrna Technologies Inc. produced more free cash flow last quarter ($8.1M vs $-23.1M). Over the past eight quarters, Byrna Technologies Inc.'s revenue compounded faster (45.5% CAGR vs -12.2%).

Byrna Technologies Inc. designs, manufactures and markets innovative less-lethal personal safety and self-defense products, including handheld kinetic launchers, specialized non-lethal projectiles and related accessories. Its core customer segments cover individual consumers, law enforcement agencies, private security firms and educational institutions, with primary markets across North America and expanding global distribution networks.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

BYRN vs LAB — Head-to-Head

Bigger by revenue
BYRN
BYRN
1.8× larger
BYRN
$35.2M
$19.6M
LAB
Growing faster (revenue YoY)
BYRN
BYRN
+37.4% gap
BYRN
26.0%
-11.5%
LAB
Higher net margin
BYRN
BYRN
187.0% more per $
BYRN
9.5%
-177.4%
LAB
More free cash flow
BYRN
BYRN
$31.2M more FCF
BYRN
$8.1M
$-23.1M
LAB
Faster 2-yr revenue CAGR
BYRN
BYRN
Annualised
BYRN
45.5%
-12.2%
LAB

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
BYRN
BYRN
LAB
LAB
Revenue
$35.2M
$19.6M
Net Profit
$3.4M
$-34.7M
Gross Margin
59.8%
48.5%
Operating Margin
11.2%
-168.5%
Net Margin
9.5%
-177.4%
Revenue YoY
26.0%
-11.5%
Net Profit YoY
-65.2%
-28.8%
EPS (diluted)
$0.14
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BYRN
BYRN
LAB
LAB
Q4 25
$35.2M
Q3 25
$28.2M
$19.6M
Q2 25
$28.5M
$21.8M
Q1 25
$26.2M
$40.8M
Q4 24
$28.0M
Q3 24
$20.9M
$22.1M
Q2 24
$20.3M
$22.5M
Q1 24
$16.7M
$45.5M
Net Profit
BYRN
BYRN
LAB
LAB
Q4 25
$3.4M
Q3 25
$2.2M
$-34.7M
Q2 25
$2.4M
$-33.5M
Q1 25
$1.7M
$-26.0M
Q4 24
$9.7M
Q3 24
$1.0M
$-26.9M
Q2 24
$2.1M
$-45.7M
Q1 24
$17.0K
$-32.2M
Gross Margin
BYRN
BYRN
LAB
LAB
Q4 25
59.8%
Q3 25
60.1%
48.5%
Q2 25
61.6%
48.8%
Q1 25
60.8%
48.4%
Q4 24
62.8%
Q3 24
62.4%
54.9%
Q2 24
62.0%
46.1%
Q1 24
57.9%
53.1%
Operating Margin
BYRN
BYRN
LAB
LAB
Q4 25
11.2%
Q3 25
10.2%
-168.5%
Q2 25
11.7%
-118.1%
Q1 25
6.5%
-80.8%
Q4 24
14.6%
Q3 24
4.0%
-120.9%
Q2 24
9.4%
-134.5%
Q1 24
-1.0%
-132.2%
Net Margin
BYRN
BYRN
LAB
LAB
Q4 25
9.5%
Q3 25
7.9%
-177.4%
Q2 25
8.5%
-153.7%
Q1 25
6.3%
-63.8%
Q4 24
34.6%
Q3 24
4.9%
-122.0%
Q2 24
10.2%
-203.3%
Q1 24
0.1%
-70.6%
EPS (diluted)
BYRN
BYRN
LAB
LAB
Q4 25
$0.14
Q3 25
$0.09
$-0.09
Q2 25
$0.10
$-0.09
Q1 25
$0.07
$-0.07
Q4 24
$0.42
Q3 24
$0.04
$-0.07
Q2 24
$0.09
$-0.12
Q1 24
$0.00
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BYRN
BYRN
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$15.5M
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$65.8M
$399.7M
Total Assets
$84.5M
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BYRN
BYRN
LAB
LAB
Q4 25
$15.5M
Q3 25
$9.0M
$129.4M
Q2 25
$158.6M
Q1 25
$19.3M
$150.9M
Q4 24
$25.7M
Q3 24
$20.1M
$210.6M
Q2 24
$24.8M
$269.8M
Q1 24
$24.2M
$287.1M
Total Debt
BYRN
BYRN
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
BYRN
BYRN
LAB
LAB
Q4 25
$65.8M
Q3 25
$63.1M
$399.7M
Q2 25
$60.1M
$424.5M
Q1 25
$56.8M
$454.6M
Q4 24
$54.4M
Q3 24
$44.5M
$489.3M
Q2 24
$45.3M
$510.3M
Q1 24
$43.2M
$577.3M
Total Assets
BYRN
BYRN
LAB
LAB
Q4 25
$84.5M
Q3 25
$78.6M
$539.6M
Q2 25
$557.0M
Q1 25
$71.0M
$579.6M
Q4 24
$71.9M
Q3 24
$59.0M
$681.5M
Q2 24
$57.5M
$708.7M
Q1 24
$52.7M
$777.7M
Debt / Equity
BYRN
BYRN
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BYRN
BYRN
LAB
LAB
Operating Cash FlowLast quarter
$9.9M
$-22.2M
Free Cash FlowOCF − Capex
$8.1M
$-23.1M
FCF MarginFCF / Revenue
23.1%
-118.1%
Capex IntensityCapex / Revenue
5.1%
4.5%
Cash ConversionOCF / Net Profit
2.95×
TTM Free Cash FlowTrailing 4 quarters
$-9.2M
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BYRN
BYRN
LAB
LAB
Q4 25
$9.9M
Q3 25
$-2.3M
$-22.2M
Q2 25
$-5.5M
$-20.7M
Q1 25
$-3.8M
$-30.3M
Q4 24
$7.3M
Q3 24
$-1.4M
$-27.9M
Q2 24
$1.9M
$-39.0M
Q1 24
$3.9M
$-62.5M
Free Cash Flow
BYRN
BYRN
LAB
LAB
Q4 25
$8.1M
Q3 25
$-4.5M
$-23.1M
Q2 25
$-6.4M
$-22.6M
Q1 25
$-6.4M
$-35.3M
Q4 24
$6.3M
Q3 24
$-2.1M
$-30.1M
Q2 24
$1.4M
$-41.0M
Q1 24
$3.8M
$-63.3M
FCF Margin
BYRN
BYRN
LAB
LAB
Q4 25
23.1%
Q3 25
-16.0%
-118.1%
Q2 25
-22.4%
-103.6%
Q1 25
-24.5%
-86.6%
Q4 24
22.5%
Q3 24
-10.0%
-136.4%
Q2 24
7.0%
-182.2%
Q1 24
22.6%
-138.9%
Capex Intensity
BYRN
BYRN
LAB
LAB
Q4 25
5.1%
Q3 25
8.0%
4.5%
Q2 25
3.3%
8.7%
Q1 25
10.1%
12.4%
Q4 24
3.4%
Q3 24
3.3%
10.2%
Q2 24
2.6%
8.6%
Q1 24
1.0%
1.7%
Cash Conversion
BYRN
BYRN
LAB
LAB
Q4 25
2.95×
Q3 25
-1.01×
Q2 25
-2.25×
Q1 25
-2.27×
Q4 24
0.75×
Q3 24
-1.36×
Q2 24
0.93×
Q1 24
231.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BYRN
BYRN

E Commerce$23.0M65%
Wholesale Dealerdistributors$10.9M31%
Other$1.3M4%

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons